Department of Surgical Oncology, First Affiliated Hospital, Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi Province, 710061, P. R. China.
Int J Biol Sci. 2011;7(5):664-72. doi: 10.7150/ijbs.7.664. Epub 2011 May 24.
Steroid receptor coactivator-3 (SRC-3), also known as AIB1, is a member of the p160 steroid receptor coactivator family. Since SRC-3 was found to be amplified in breast cancer in 1997, the role of SRC-3 in cancer has been broadly investigated. SRC-3 initially was identified as a transcriptional coactivator for nuclear receptors such as the estrogen receptor (ER), involved in the proliferation of hormone-dependent cancers. However, increasing clinical evidence shows that dysregulation of SRC-3 expression in several human hormone-independent cancers is correlated with pathological factors and clinical prognosis. Recently, both in vivo and in vitro studies demonstrate that SRC-3 may influence a number of cancer cellular processes in several ways independent of nuclear receptor signaling. In addition, an SRC-3 transgenic mice model shows that SRC-3 induces tumors in several mouse tissues. These results indicate that the role of SRC-3 in cancer is not just as a nuclear receptor coactivator. The focus of this review is to examine possible SRC-3 roles in cancer, other than as a nuclear receptor coactivator.
类固醇受体共激活因子-3（SRC-3），也称为 AIB1，是 p160 类固醇受体共激活因子家族的一员。自 1997 年发现 SRC-3 在乳腺癌中扩增以来，SRC-3 在癌症中的作用已被广泛研究。SRC-3 最初被鉴定为核受体（如雌激素受体（ER））的转录共激活因子，参与激素依赖性癌症的增殖。然而，越来越多的临床证据表明，几种人类非激素依赖性癌症中 SRC-3 表达的失调与病理因素和临床预后相关。最近，体内和体外研究都表明，SRC-3 可能通过独立于核受体信号的多种方式影响多种癌症细胞过程。此外，SRC-3 转基因小鼠模型表明，SRC-3 可在几种小鼠组织中诱导肿瘤。这些结果表明，SRC-3 在癌症中的作用不仅仅是作为核受体共激活因子。本综述的重点是研究 SRC-3 在癌症中除作为核受体共激活因子以外的可能作用。
